Boehringer Ingelheim Introduces COPD Treatment in Domestic Market

Published: 2005-01-24 06:58:00

Updated: 2005-01-24 06:58:00

Boehringer Ingelheim Korea and Pfizer Korea announced that Spiriva HandiHaler (tiotropium bromide), for the treatment of COPD (Chronic Obstructive Pulmonary Disease), will be available in the domestic market starting February 1st.

Discovered and developed by Boehringer Ingelheim, Spiriva will ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK